ArticleJCO precision oncology2025

Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer.

Marcia S Brose et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.